RecruitingNCT03818503
E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Enrollment
2,000 participants
Start Date
Jun 24, 2019
Study Type
OBSERVATIONAL
Conditions
Summary
The primary objective is the collection of real-world data of cancer patients treated with radiotherapy, to support radiotherapy research and to provide evidence of the role of radiation oncology in a multidisciplinary approach. This is an open ended prospective non-interventional non-therapeutic multi-cohort study.
Eligibility
Min Age: 12 Years
Inclusion Criteria5
- Pathologically confirmed cancer.
- Written informed consent for E²-RADIatE according to applicable legal and ethical requirements
- Planned use of radiotherapy
- Eligibility of the patient confirmed for at least one cohort confirmed
- Patients of 12 years and older
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(77)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03818503
Related Trials
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
NCT055881411 location
Patient-Centered Assessment of Symptoms and Outcomes
NCT039526241 location
Tumor Related Epilepsy
NCT026393251 location
Improving Engagement in HIV and Cancer Care in Zimbabwe
NCT069343691 location
Study of a Support Program for Quality of Life in Chinese Cancer Patients and Survivors
NCT074543307 locations